Medtronic (MDT)
Medtronic (MDT) Stock Price, Analysis & Data
| Bid | 89.51 |
| Market Cap | 114.88B |
| Revenue (ttm) | 36.36B |
| Net Income (ttm) | 4.8B |
| Beta | 0.57 |
| EPS (ttm) | 3.73 |
| PE Ratio (ttm) | 24.06 |
| Forward PE | 14 |
| P/B (ttm) | 2.32 |
| P/S (ttm) | 3.16 |
| Earnings Date | Sep 1, 2026 |
| Ask | 89.55 |
| Volume | 1,561,939 |
| Avg. Volume (20D) | 9,440,495 |
| Open | 88.96 |
| Previous Close | 90.68 |
| Day's Range | 88.50 - 89.89 |
| 52-Week Range | 73.31 - 106.33 |
| Analyst | Buy |
| Price Target | 100 (11.42%) |
| Dividends | $2.88 (3.18%) |
| Ex-Dividend Date | Jun 26, 2026 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization th...
Financial Performance
In 2026, Medtronic's revenue was 36.36B, an increase of 8.43% compared to the previous year's 33.54B. Earnings were 4.8B, an increase of 2.98%.
Financial StatementsAnalyst Forecast
According to 25 analyst ratings, the average rating for MDT stock is "Buy". The 12-month stock price forecast is 100, which is upside of 11.42% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
